ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "depression"

  • Abstract Number: 1584 • ACR Convergence 2021

    Relation of Depressive Symptoms to Alterations in Conditioned Pain Modulation in Knee Osteoarthritis: The Multicenter Osteoarthritis Study (MOST)

    Kosaku Aoyagi1, Lisa Carlesso2, Laura Frey-Law3, Gabriela Rabasa4, Cora Lewis5, Michael Nevitt6 and Tuhina Neogi7, 1Boston University, Quincy, MA, 2McMaster University, Hamilton, ON, Canada, 3University of Iowa, Iowa City, IA, 4Boston University, Boston, MA, 5University of Alabama Birmingham, Birmingham, AL, 6University of California San Francisco, Orinda, CA, 7Boston University School of Medicine, Boston, MA

    Background/Purpose: Inefficiency of descending conditioned pain modulation (CPM) is present in 42-55% of individuals with knee osteoarthritis (OA), which can contribute to more pain and…
  • Abstract Number: 0121 • ACR Convergence 2021

    The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression

    Josefina Duran, Alvaro Verges, Ana Rocío Vázquez-Taboada, Matias Gonzalez and Lydia Gomez-Pérez, Pontificia Universidad Católica de Chile, Santiago, Chile

    Background/Purpose: Fibromyalgia (FM) and major depression frequently coexist. Patients with both conditions have a worse prognosis and higher disability, and their treatment options are scarce.…
  • Abstract Number: 1659 • ACR Convergence 2021

    Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database

    jens Pedersen1, Lei Wang2, Alma Pedersen2, Kjeld Andersen3, Claus Sørensen3 and Torkell Ellingsen4, 1Department of Medicine M, Section of Rheumatology, Svendborg Hospital, Odense University Hospital, Svendborg, Denmark, Odense, Denmark, 2Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 3Department of Mental Health, Odense, Odense, Denmark, 4Rheumatology Research Unit, Department of Rheumatology C, Odense University Hospital, Odense, Denmark

    Background/Purpose: Depression occurs with a prevalence of about 17% (95% confidence interval (CI): 10-24) in patients with RA (1) and both disorders may share common…
  • Abstract Number: 0225 • ACR Convergence 2021

    Prevalence of Sexual Dysfunction and Depression in German Patients with Psoriasis and Psoriatic Arthritis – Results of the PIPPA Study

    Sebastian Saur1, Alexandra Schloegl2, Caroline Höppner3, Anastasia Gubar2, Katharina Meier4, Matthias Hahn2 and Jorg Henes2, 1Universtiy Hostpiatl Tübingen, Tuebingen, Germany, 2University Hospital Tuebingen, Tuebingen, Germany, 3Charite Berlin, Berlin, Germany, 4Department of Dermatology, Venereology and Allergology – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany

    Background/Purpose: As known chronic inflammatory diseases have an impact on sexuality. To date, there are only a few studies from North and Latin America which…
  • Abstract Number: 1667 • ACR Convergence 2021

    Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression

    Yusuke Miwa1, Yoshiaki Ohashi2, Hajime Tomatsu3 and Yuko Mitamura4, 1Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, 2HMT Biomedical Inc., Yokohama, Japan, 3HMT Biomedical Inc., Chuo, Japan, 4Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan

    Background/Purpose: The odds of patients with rheumatoid arthritis (RA) experiencing depression is 1.42 (95% CI: 1.3–1.5; approximately 15% of patients) compared with healthy individuals. Diagnosis…
  • Abstract Number: 0236 • ACR Convergence 2021

    Maternal Attachment, Anxiety and Depressive Symptoms in Pregnant Women with Rheumatic Diseases

    Luis Gerardo Espinosa-Banuelos1, Diana Carolina Rubio Torres2, Maria Corral2, Cassandra Skinner Taylor2, Lorena Perez-Barbosa2, Luz Fernanda Gutierrez Leal2, Abraham Yair Lujano-Negrete3, Jesus Cardenas-de La Garza2 and Dionicio Galarza-Delgado2, 1Faculty of Medicine and University Hospital Dr. Jose Eleuterio Gonzalez, UANL, Monterrey, Mexico, 2Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, 3Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico

    Background/Purpose: Untreated perinatal anxiety symptomatology can be related to symptoms of anxiety and depression during the postpartum. The psychological bond created by the mother between…
  • Abstract Number: 1672 • ACR Convergence 2021

    Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA

    Susan Bartlett1, Dana DiRenzo2, Michelle Jones3 and Clifton Bingham2, 1McGill University, Montréal, QC, Canada, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins Medicine, Baltimore, MD

    Background/Purpose: Rheumatic diseases (RD) are chronic conditions that require potent immunosuppressants to control systemic inflammation. Fears associated with increased vulnerability from being on immunosuppressants plus…
  • Abstract Number: 0308 • ACR Convergence 2021

    Sleep Disorders and Serum Brain-derived Neurotrophic Factor Levels in Patients with Primary Sjögren’s Syndrome

    Yaxin Han1, Li Long2, Xixi Chen2, Qing Peng2, GUO TANG3, Jiajun Liu2 and Yan Liu2, 1The People's Hospital of Wenjiang,China; Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China;Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China (People's Republic), 2Department of Rheumatology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China (People's Republic), 3Chongqing Bishan People's Hospital, Chongqing, China (People's Republic)

    Background/Purpose: This study aimed to evaluate the sleep quality and its influenced factors in patients with primary Sjögren's syndrome (pSS), and another purpose is to…
  • Abstract Number: 1673 • ACR Convergence 2021

    Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions

    Orit Schieir1, Susan Bartlett2, Marie-France Valois2, Louis Bessette3, Gilles Boire4, Glen Hazlewood5, Carol Hitchon6, Edward Keystone7, Janet Pope8, Diane Tin9, Carter Thorne10, Vivian Bykerk11 and CATCH Investigators12, 1Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada, 5University of Calgary, Calgary, AB, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9The Arthritis Program Research Group, Newmarket, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY, 12Mt Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: During the COVID-19 pandemic, Canadians adults with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and…
  • Abstract Number: 0627 • ACR Convergence 2021

    Increasing Rates of Standardized Depression Screening in Adolescents and Young Adults with Childhood-Onset Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic

    Emily Datyner1, Manda Mitchell1, Brooke Fine1, Barron Patterson1, T. Brent Graham1 and Alaina Davis2, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt Universty Medical Center, Nashville, TN

    Background/Purpose: Depression is common and adversely affects health outcomes in adolescents and young adults with childhood-onset systemic lupus erythematous (cSLE).1,2 The aim of our quality…
  • Abstract Number: 0655 • ACR Convergence 2021

    Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis

    Rosa Morlà1, Beatriz Frade-Sosa2, Núria Sapena3, Roberto Gumucio2, Raimon Sanmarti2 and Jose A Gomez-Puerta2, 1Hospital Universitari Clinic de Barcelona, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Rheumatology Department, Hospital Clínic, Barcelona, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with different comorbidities. Depression and fatigue are common in RA patients with a prevalence of 17-39-%(1) and 40%(2)…
  • Abstract Number: 0725 • ACR Convergence 2021

    Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia

    Philip Mease1, Theresa Mallick-Searle2, Elizabeth Johnston3, Lars Viktrup3, Dominique Menuet4, Ruoyong Yang5 and Robert Fountaine6, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Stanford Health Care, Redwood City, 3Eli Lilly and Company, Indianapolis, IN, 4Pfizer SAS, Paris, France, 5Pfizer Inc., New York, NY, 6Pfizer Inc., Groton, CT

    Background/Purpose: Tanezumab is a monoclonal antibody directed against nerve growth factor that is under study to treat moderate to severe chronic pain associated with osteoarthritis…
  • Abstract Number: 0166 • ACR Convergence 2020

    Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey

    Alexis Ogdie1, George Gondo2, Joseph Merola3, Stacie Bell4 and Alice Gottlieb5, 1University of Pennsylvania, Philadelphia, PA, 2National Psoriasis Foundation, Portland, OR, 3Brigham and Women's Hospital, Harvard Medical School, Newton, MA, 4National Psoriasis Foundation, Portland, 5Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Despite many efficacious therapies for PsA, many patients do not achieve remission.  Ongoing disease activity leads to many downstream effects including diminished functional ability,…
  • Abstract Number: 1598 • ACR Convergence 2020

    Efficacy of Universal Depression Screening in a Rheumatology Clinic

    Osman Bhatty1 and Michael Lucke1, 1Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Depression has long been viewed as a comorbid condition in rheumatic diseases. Population studies have confirmed an increased incidence in patients with rheumatoid arthritis,…
  • Abstract Number: 0194 • ACR Convergence 2020

    Depression Symptoms but Not Clinically Diagnosed Depression Predict Mortality in Rheumatoid Arthritis

    Jose Felix Restrepo1, Inmaculada Del Rincon1 and Agustin Escalante1, 1University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX

    Background/Purpose: Depression and depressive symptoms are common but under-recognized in rheumatoid arthritis (RA). Few studies have examined depression symptoms in RA patients compared to clinically…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology